Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 6Gastro-enteropancreatic neuroendocrine tumor 3Somatostatin Receptor-positive Neuroendocrine Tumor 1Somatostatin Receptor-positive GEP-NET 1Pheochromocytoma 1Paraganglioma 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer 1Advanced Neuroendocrine Neoplasm 1

Interventions

3-Iodobenzylguanidine 5spartalizumab 1lutetium Lu 177 dotatate 1copper dotatate CU-64 1belzutifan 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Melphalan 1Lutetium-177 1Lutetium 1Iodine-131 1Immunotherapy 1Everolimus 1Drug Therapy 1Biological Therapy 13-fluorobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pheochromocytoma × lutetium Lu 177 dotatate × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡